RMIT University
Browse

Bone marrow-derived mesenchymal stem cells mitigate chronic colitis and enteric neuropathy via anti-inflammatory and anti-oxidative mechanisms

Download (9.94 MB)
journal contribution
posted on 2025-10-27, 22:25 authored by Rhian Stavely, Ainsley M Robinson, Sarah Fraser, Rhiannon T Filippone, Vanesa Stojanovska, Rajaraman EriRajaraman Eri, Vasso ApostolopoulosVasso Apostolopoulos, Samy Sakkal, Kulmira Nurgali
Current treatments for inflammatory bowel disease (IBD) are often inadequate due to limited efficacy and toxicity, leading to surgical resection in refractory cases. IBD’s broad and complex pathogenesis involving the immune system, enteric nervous system, microbiome, and oxidative stress requires more effective therapeutic strategies. In this study, we investigated the therapeutic potential of bone marrow-derived mesenchymal stem cell (BM-MSC) treatments in spontaneous chronic colitis using the Winnie mouse model which closely replicates the presentation and inflammatory profile of ulcerative colitis. The 14-day BM-MSC treatment regimen reduced the severity of colitis, leading to the attenuation of diarrheal symptoms and recovery in body mass. Morphological and histological abnormalities in the colon were also alleviated. Transcriptomic analysis demonstrated that BM-MSC treatment led to alterations in gene expression profiles primarily downregulating genes related to inflammation, including pro-inflammatory cytokines, chemokines and other biomarkers of inflammation. Further evaluation of immune cell populations using immunohistochemistry revealed a reduction in leukocyte infiltration upon BM-MSC treatment. Notably, enteric neuronal gene signatures were the most impacted by BM-MSC treatment, which correlated with the restoration of neuronal density in the myenteric ganglia. Moreover, BM-MSCs exhibited neuroprotective effects against oxidative stress-induced neuronal loss through antioxidant mechanisms, including the reduction of mitochondrial-derived superoxide and attenuation of oxidative stress-induced HMGB1 translocation, potentially relying on MSC-derived SOD1. These findings suggest that BM-MSCs hold promise as a therapeutic intervention to mitigate chronic colitis by exerting anti-inflammatory effects and protecting the enteric nervous system from oxidative stress-induced damage.<p></p>

Funding

National Health and Medical Research Council

Crohn's and Colitis Foundation

Department of Employment and Workplace Relations

History

Related Materials

  1. 1.
  2. 2.
  3. 3.
    PMID - Has metadata PubMed 38503815
  4. 4.
    PMID - Has metadata PubMed PMC10951223
  5. 5.
    DOI - Is published in DOI: 10.1038/s41598-024-57070-6
  6. 6.
    ISSN - Is published in 2045-2322 (Scientific Reports)

Journal

Scientific Reports

Volume

14

Number

6649

Total pages

16

Publisher

Springer Nature

Language

eng

Copyright

© The Author(s) 2024

Open access

  • Yes

Usage metrics

    Scholarly Works

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC